PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Tau Spread, Apolipoprotein E, Inflammation, and More: Rapidly Evolving Basic Science in Alzheimer Disease.

Abstract To date, Alzheimer disease drug candidates have produced negative results in human trials, and progress in moving new targets out of the laboratory and into trials has been slow. However, based on 3 decades of previous work, there is reason to hope that amyloid-based and other novel therapies will move at a faster pace toward successful clinical trials. This article highlights selected preclinical research topics that are rapidly advancing in the laboratory.
PMID
Related Publications

Apolipoprotein E epsilon4 does not modulate amyloid-β-associated neurodegeneration in preclinical Alzheimer disease.

Potential novel targets for Alzheimer pharmacotherapy: II. Update on secretase inhibitors and related approaches.

Core candidate neurochemical and imaging biomarkers of Alzheimer's disease.

Translational research on the way to effective therapy for Alzheimer disease.

Alzheimer disease therapy--moving from amyloid-β to tau.

Authors

Mayor MeshTerms
Keywords

Cholesterol

Imaging flow cytometry

Microglia

Oligomer

Synapse

Journal Title neurologic clinics
Publication Year Start




PMID- 28410655
OWN - NLM
STAT- In-Process
DA  - 20170415
LR  - 20170415
IS  - 1557-9875 (Electronic)
IS  - 0733-8619 (Linking)
VI  - 35
IP  - 2
DP  - 2017 May
TI  - Tau Spread, Apolipoprotein E, Inflammation, and More: Rapidly Evolving Basic
      Science in Alzheimer Disease.
PG  - 175-190
LID - S0733-8619(17)30001-4 [pii]
LID - 10.1016/j.ncl.2017.01.001 [doi]
AB  - To date, Alzheimer disease drug candidates have produced negative results in
      human trials, and progress in moving new targets out of the laboratory and into
      trials has been slow. However, based on 3 decades of previous work, there is
      reason to hope that amyloid-based and other novel therapies will move at a faster
      pace toward successful clinical trials. This article highlights selected
      preclinical research topics that are rapidly advancing in the laboratory.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Gonzalez, Bianca
AU  - Gonzalez B
AD  - UCLA School of Nursing, Box 956919, Factor Building 6-266, Los Angeles, CA 90095,
      USA.
FAU - Abud, Edsel M
AU  - Abud EM
AD  - Institute for Memory Impairments and Neurological Disorders, UC Irvine, 2642
      Biological Sciences III, Irvine, CA 92697-4545, USA.
FAU - Abud, Abigail M
AU  - Abud AM
AD  - Institute for Memory Impairments and Neurological Disorders, UC Irvine, 2642
      Biological Sciences III, Irvine, CA 92697-4545, USA.
FAU - Poon, Wayne W
AU  - Poon WW
AD  - Institute for Memory Impairments and Neurological Disorders, UC Irvine, 2642
      Biological Sciences III, Irvine, CA 92697-4545, USA.
FAU - Gylys, Karen H
AU  - Gylys KH
AD  - UCLA School of Nursing, Box 956919, Factor Building 6-266, Los Angeles, CA 90095,
      USA. Electronic address: [email protected]
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Neurol Clin
JT  - Neurologic clinics
JID - 8219232
OTO - NOTNLM
OT  - Cholesterol
OT  - Imaging flow cytometry
OT  - Microglia
OT  - Oligomer
OT  - Synapse
EDAT- 2017/04/16 06:00
MHDA- 2017/04/16 06:00
CRDT- 2017/04/16 06:00
AID - S0733-8619(17)30001-4 [pii]
AID - 10.1016/j.ncl.2017.01.001 [doi]
PST - ppublish
SO  - Neurol Clin. 2017 May;35(2):175-190. doi: 10.1016/j.ncl.2017.01.001.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>